Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 170

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience

Chapman, Louisa E, Mertz, Gregory J, Peters, Clarence J, Jolson, Heidi M, Khan, Ali S, Ksiazek, Thomas G, Koster, Frederick T, Baum, Kenneth F, Rollin, Pierre E, Pavia, Andrew T, Holman, Robert C, Christenson, John C, Rubin, Phillip J, Behrman, Rachel E, Bell, Linda J Wilson, Simpson, Gary L, Sadek, Ramses F, The Ribavirin Study Group, Armstrong, B, Atterbury, BT, Baacke, G, Bellardi, D, Carroll, M, Cheek, J, Craig, A, Daniels, D, Freeman, W, Held, F, Kessler, D, Konicck, S, Light, A, McGee, J, Savage, J, Sloan, M, Tempest, B, Vaughan, K, Waite, D, Becher, J, Brieman, R, Bulter, J, Schmidt-Dalton, MJ, Hart, DC, Hawk, J, Khabbaz, R, Lloyd, E, Sortir, M, Stokes, S, Torok, TJ, Vitek, C, Harding;, S, England, R, Kioski, C, Mosley, D, Sands, L, Johnson-Baach, T, Ronnau, KJ, Mast, DD, Servi, R, Levinson, R, Yeager, FS, Adam, R, Friedman, B, Lincoln, L, Petersen, EA, Wack, E, Moncada, R, Bassi, S Singh, Rumack, JS, Kuriyama, S, McGovern, J, Olson, D, Garst, P, Butera, ML, Erlich, K, Dinolfo, M, Dalton, C, Hoffman, R, Kuritzkes, D, Madinger, N, Schooley, R, Mass, A, Hofflin, JM, Britton, K, Blum, R, Cott, G, Golub, B, Greenberg, K, Lichtenstien, K, O'Brien, R, Motley, RF, Culliman, M, Fujeta, N, Mason, S, McLeod, GX, Mateos-Mora, M, Demers, D, Jackson, C, Zar, B, Ramakrishna, B, Jones, CL, Lucht, W, Conrad, S, Grier, LR, King, JW, Adelso, J, Kim-Karpe, M, Bergman, M, Schut, R, Sterling, T, Brewer, JH, Anderson, DE, Roehrs, J, Dietrich, JE, Jones, D, Ward, C, Stockfish, JF, Allen, S, Crowell, RE, Cushing, A, Goade, D, Irizarry, L, Jenison, S, Levy, H, Overturf, G, Palmer, D, Quenzer, R, Reed, W, Simpson, S, Williams, J, Berger, BJ, Hussain, F, Berger, B, Sepe, F, Hargreaves, J, Baddour, LM, Parrish, R, Plemmons, R, Radolf, J, Szeyko, G, Elkind, K, Knight, V, Badger, MS, Furlan, J, Gillum, M, Tice, AD, Barany, J·1999·Antiviral Therapy

Abstract

Intravenous ribavirin was provided non-selectively for investigational open-label use among persons with suspected hantavirus pulmonary syndrome (HPS) in the United States between 4 June 1993 and 1 September 1994. Therapy was initiated prior to laboratory confirmation of hantavirus infection because most deaths from HPS occur within 48 h of hospitalization. Thirty patients with confirmed HPS, 105 patients without HPS and 5 patients without adequate diagnostic testing for HPS were enrolled. This observational study arguably provides the most complete information available on ribavirin-associated adverse effects. Although ribavirin was generally well tolerated, 71% of recipients became anaemic and 19% underwent transfusion. An apparent excess of hyperamylasaemia/pancreatitis was either therapy-associated or due to enrolment bias. The 30 enrolled HPS patients had a case–fatality rate of 47% (14/30). It is not possible to assess efficacy with this study design. However, comparison of survival curves for the 30 enrolled HPS patients and 34 patients who developed HPS during the same time period but were not enrolled did not suggest an appreciable drug effect. A randomized, placebo-controlled trial that enrols patients during the prodrome phase would be necessary to assess the efficacy and further define the safety of intravenous ribavirin for HPS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/135965359900400404

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 170

Metadata

Authors
Chapman, L. E., Mertz, G. J., Peters, C. J., Jolson, H. M., Khan, A. S., Ksiazek, T. G., Koster, F. T., Baum, K. F., Rollin, P. E., Pavia, A. T., Holman, R. C., Christenson, J. C., Rubin, P. J., Behrman, R. E., Bell, L. J. W., Simpson, G. L., Sadek, R. F., The Ribavirin Study Group, Armstrong, B., Atterbury, B., Baacke, G., Bellardi, D., Carroll, M., Cheek, J., Craig, A., Daniels, D., Freeman, W., Held, F., Kessler, D., Konicck, S., Light, A., McGee, J., Savage, J., Sloan, M., Tempest, B., Vaughan, K., Waite, D., Becher, J., Brieman, R., Bulter, J., Schmidt-Dalton, M., Hart, D., Hawk, J., Khabbaz, R., Lloyd, E., Sortir, M., Stokes, S., Torok, T., Vitek, C., Harding;, S., England, R., Kioski, C., Mosley, D., Sands, L., Johnson-Baach, T., Ronnau, K., Mast, D., Servi, R., Levinson, R., Yeager, F., Adam, R., Friedman, B., Lincoln, L., Petersen, E., Wack, E., Moncada, R., Bassi, S. S., Rumack, J., Kuriyama, S., McGovern, J., Olson, D., Garst, P., Butera, M., Erlich, K., Dinolfo, M., Dalton, C., Hoffman, R., Kuritzkes, D., Madinger, N., Schooley, R., Mass, A., Hofflin, J., Britton, K., Blum, R., Cott, G., Golub, B., Greenberg, K., Lichtenstien, K., O'Brien, R., Motley, R., Culliman, M., Fujeta, N., Mason, S., McLeod, G., Mateos-Mora, M., Demers, D., Jackson, C., Zar, B., Ramakrishna, B., Jones, C., Lucht, W., Conrad, S., Grier, L., King, J., Adelso, J., Kim-Karpe, M., Bergman, M., Schut, R., Sterling, T., Brewer, J., Anderson, D., Roehrs, J., Dietrich, J., Jones, D., Ward, C., Stockfish, J., Allen, S., Crowell, R., Cushing, A., Goade, D., Irizarry, L., Jenison, S., Levy, H., Overturf, G., Palmer, D., Quenzer, R., Reed, W., Simpson, S., Williams, J., Berger, B., Hussain, F., Berger, B., Sepe, F., Hargreaves, J., Baddour, L., Parrish, R., Plemmons, R., Radolf, J., Szeyko, G., Elkind, K., Knight, V, Badger, M., Furlan, J., Gillum, M., Tice, A., & Barany, J.
Venue
Antiviral Therapy
Published
1999-05
Volume
4
Issue
4
Pages
211-219
ISSN
  • 1359-6535 (ISSN-L)
  • 2040-2058
OpenAlex
W192855520
Cited by
170
References
2
FWCI
4.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience. https://app.cochat.ai/papers/10.1177/135965359900400404
The paper
Chapman, L. E., Mertz, G. J., Peters, C. J., Jolson, H. M., Khan, A. S., Ksiazek, T. G., Koster, F. T., Baum, K. F., Rollin, P. E., Pavia, A. T., Holman, R. C., Christenson, J. C., Rubin, P. J., Behrman, R. E., Bell, L. J. W., Simpson, G. L., Sadek, R. F., The Ribavirin Study Group, Armstrong, B., . . . Barany, J. (1999). Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience. Antiviral Therapy. https://doi.org/10.1177/135965359900400404

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.